Hereditary alpha tryptasemia: literature overview on the genetic trait and its clinical manifestations
Authors:
Open Access
- 8 September 2023
- journal article
- Published by VM Media Group sp. z o.o in Forum Dermatologicum
Abstract
Hereditary Alpha Tryptasemia (HαT) is a genetic condition characterized by an increased number of copies of the TPSAB1 gene, resulting in elevated basal serum tryptase levels and an increased risk of anaphylaxis, especially in individuals with IgE-dependent allergies or systemic mastocytosis. The severity of clinical symptoms can vary and is influenced by the number of extra TPSAB1 gene copies, suggesting a gene-dose effect. Approximately two-thirds of individuals with HαT show minimal or no symptoms. The remaining individuals with HαT may present with Hymenoptera venom allergy, flushing, urticarial/angioedema, irritable bowel syndrome, gastrointestinal reflux, hypermobility, neuropsychiatric symptoms and dysautonomia. Recent studies revealed that α-tryptase which forms complexes with β-tryptase activate protease-activated receptor-2 (PAR2) receptors. Activation of these receptors may lead to hypotension, muscle contraction, inflammation, and trigger neuropeptide secretion, and in consequence, result in mast cell degranulation. This cycle of activation and degranulation may potentially contribute to the development of mast cell activation syndrome (MCAS). Mast cell activation syndromes are defined by systemic, severe and recurrent mast cell activations, usually in the form of anaphylaxis. Hereditary/ familial MCAS is a specific subtype of MCAS, which is associated with HαT. Diagnostic work-up for HαT includes determination of basal serum tryptase level and the presence of additional TPSAB1 gene copies using droplet digital polymerase chain reaction. Further research is needed, to explore the relationship between HαT and MCAS, as well as to determine if there is a distinct form of hereditary MCAS which is independent of HαT. These investigations aim to improve diagnostic approaches and treatment strategies for individuals with HαT, enhancing their management and overall quality of life. Hereditary Alpha Tryptasemia (HαT) is a genetic condition characterized by an increased number of copies of the TPSAB1 gene, resulting in elevated basal serum tryptase levels and an increased risk of anaphylaxis, especially in individuals with IgE-dependent allergies or systemic mastocytosis. The severity of clinical symptoms can vary and is influenced by the number of extra TPSAB1 gene copies, suggesting a gene-dose effect. Approximately two-thirds of individuals with HαT show minimal or no symptoms. The remaining individuals with HαT may present with Hymenoptera venom allergy, flushing, urticarial/angioedema, irritable bowel syndrome, gastrointestinal reflux, hypermobility, neuropsychiatric symptoms and dysautonomia. Recent studies revealed that α-tryptase which forms complexes with β-tryptase activate protease-activated receptor-2 (PAR2) receptors. Activation of these receptors may lead to hypotension, muscle contraction, inflammation, and trigger neuropeptide secretion, and in consequence, result in mast cell degranulation. This cycle of activation and degranulation may potentially contribute to the development of mast cell activation syndrome (MCAS). Mast cell activation syndromes are defined by systemic, severe and recurrent mast cell activations, usually in the form of anaphylaxis. Hereditary/ familial MCAS is a specific subtype of MCAS, which is associated with HαT. Diagnostic work-up for HαT includes determination of basal serum tryptase level and the presence of additional TPSAB1 gene copies using droplet digital polymerase chain reaction. Further research is needed, to explore the relationship between HαT and MCAS, as well as to determine if there is a distinct form of hereditary MCAS which is independent of HαT. These investigations aim to improve diagnostic approaches and treatment strategies for individuals with HαT, enhancing their management and overall quality of life.Keywords
This publication has 45 references indexed in Scilit:
- Hereditary alpha-tryptasemia despite normal tryptase-encoding gene copy number owing to copy number loss in transAnnals of Allergy, Asthma & Immunology, 2021
- Clinical relevance of inherited genetic differences in human tryptasesAnnals of Allergy, Asthma & Immunology, 2021
- Mast cell tryptases in allergic inflammation and immediate hypersensitivityCurrent Opinion in Immunology, 2021
- Hereditary alpha-tryptasemia in 101 patients with mast cell activation–related symptomatology including anaphylaxisAnnals of Allergy, Asthma & Immunology, 2021
- Hereditary Alpha-Tryptasemia: a Commonly Inherited Modifier of AnaphylaxisCurrent Allergy and Asthma Reports, 2021
- Clinical response to omalizumab in patients with hereditary α-tryptasemiaAnnals of Allergy, Asthma & Immunology, 2020
- Mast Cell Biology at Molecular Level: a Comprehensive ReviewClinical Reviews in Allergy & Immunology, 2019
- Hereditary Alpha TryptasemiaImmunology and Allergy Clinics of North America, 2018
- First Identification of an Inherited TPSAB1 Quintuplication in a Patient with Clonal Mast Cell DiseaseJournal of Clinical Immunology, 2018
- Expanding Spectrum of Mast Cell Activation Disorders: Monoclonal and Idiopathic Mast Cell Activation SyndromesClinical Therapeutics, 2013